Vision, Translated: José-Alain Sahel, MD, and the Business of Turning Scientific Discovery into Tangible, Life-Changing Patient Care

José Alain Sahel, MD, has spent his career at the intersection of scientific inquiry and clinical care, advancing research across gene therapy, optogenetics, retinal prosthetics, neuroprotection, and regenerative strategies for vision loss. As a practicing physician scientist, he has led and co led multiple first in human and late stage clinical trials, translating complex laboratory discoveries into therapies with measurable patient benefit. In his role as executive vice president of UPMC Enterprises, the venture capital arm of UPMC, Dr. Sahel brings this research driven, clinician informed perspective, helping ensure that promising innovations are evaluated, validated, and advanced with both scientific integrity and patient outcomes at the forefront at UPMC and beyond. Learn more about Dr. Sahel’s translational approach at go.upmc.com/prpp-sahel.